Hinova Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	436.79	438.18	633.44	813.23	1,202	901.22
Trading Asset Securities	390.95	310.59	210.49	290.62	366.24	-
Cash & Short-Term Investments	827.74	748.77	843.93	1,104	1,568	901.22
Cash Growth	5.76%	-11.28%	-23.55%	-29.59%	73.97%	-20.85%
Accounts Receivable	3.08	0	-	-	-	-
Other Receivables	1.05	0.51	0.84	1.39	1.67	0.54
Receivables	4.13	0.52	0.84	1.39	1.67	0.54
Inventory	4.7	2.85	0	0.01	0.01	0
Prepaid Expenses	-	-	-	-	-	13.09
Other Current Assets	44.25	154.2	40.77	41.99	41.78	40.38
Total Current Assets	880.83	906.34	885.54	1,147	1,611	955.24
Property, Plant & Equipment	357.66	356.03	328.62	187.99	86.61	12.72
Long-Term Investments	13.8	13.8	113.09	109.98	5	-
Other Intangible Assets	30.95	31.08	30.56	31.21	31.86	-
Long-Term Deferred Charges	-	-	-	0.04	0.08	-
Other Long-Term Assets	2.64	2.51	3.77	15.12	0.21	14.39
Total Assets	1,286	1,310	1,362	1,492	1,735	982.35
Accounts Payable	91.52	88.55	40.63	3.14	2.29	1.31
Accrued Expenses	4.86	8.43	31.09	49.17	69.81	90.45
Short-Term Debt	-	-	-	-	30	-
Current Portion of Long-Term Debt	2.93	3.3	-	-	-	-
Current Portion of Leases	-	-	3.22	3.77	2.45	2.8
Current Income Taxes Payable	1.38	1.58	-	-	-	-
Current Unearned Revenue	4.16	3.8	-	-	-	-
Other Current Liabilities	20.24	20.25	72.01	50.76	33.73	96.77
Total Current Liabilities	125.08	125.9	146.95	106.84	138.27	191.33
Long-Term Debt	100	100	-	-	-	-
Long-Term Leases	2.11	2.59	5.83	9.08	3.31	1.11
Long-Term Unearned Revenue	24.47	17.49	16.55	8.55	8.1	1.15
Other Long-Term Liabilities	0.47	0.2	-	-	-	-
Total Liabilities	252.12	246.19	169.33	124.47	149.68	193.59
Common Stock	99.02	99.02	99.02	99.02	99.02	74.26
Additional Paid-In Capital	2,592	2,592	2,583	2,558	2,482	1,409
Retained Earnings	-1,657	-1,627	-1,490	-1,290	-996.06	-694.54
Comprehensive Income & Other	-0.22	-0.15	-0.03	0.11	0.14	-0.07
Total Common Equity	1,034	1,064	1,192	1,367	1,585	788.76
Shareholders' Equity	1,034	1,064	1,192	1,367	1,585	788.76
Total Liabilities & Equity	1,286	1,310	1,362	1,492	1,735	982.35
Total Debt	105.04	105.89	9.05	12.85	35.76	3.91
Net Cash (Debt)	722.71	642.88	834.88	1,091	1,532	897.31
Net Cash Growth	-6.67%	-23.00%	-23.48%	-28.79%	70.74%	-21.16%
Net Cash Per Share	7.33	6.51	8.41	11.02	16.87	12.07
Filing Date Shares Outstanding	99.61	99.02	99.02	99.02	99.02	74.26
Total Common Shares Outstanding	99.61	99.02	99.02	99.02	99.02	74.26
Working Capital	755.75	780.43	738.59	1,040	1,473	763.91
Book Value Per Share	10.38	10.74	12.04	13.81	16.01	10.62
Tangible Book Value	1,003	1,032	1,162	1,336	1,554	788.76
Tangible Book Value Per Share	10.07	10.43	11.73	13.49	15.69	10.62
Machinery	-	-	17.15	15.49	14.85	11.16
Construction In Progress	-	-	314.5	169.54	73.76	3

Source: S&P Global Market Intelligence. Standard template. Financial Sources.